Iterum Therapeutics

Inactive

ITRM (NGM)

Iterum Therapeutics plc develops and markets treatments for drug‑resistant infections in Ireland, Bermuda, and the United States. Its product ORLYNVAH is an oral penem antibiotic for uncomplicated UTIs caused by common pathogens in adult women with limited oral options. It is developing sulopenem, with oral and IV forms for various uncomplicated and complicated infections. Founded in 2015, it is based in Dublin, Ireland.